ライフサイエンスコーパス: immunogenic cell death

1 f tumor antigen cross-priming in contexts of immunogenic cell death.

2 nant cells that undergo chemotherapy-induced immunogenic cell death.

3 ported Ga(III) complexes capable of inducing immunogenic cell death.

4 ppressing downstream pathways and inhibiting immunogenic cell death.

5 ) treatment, indicated a strong induction of immunogenic cell death.

6 antitumor immunity through the generation of immunogenic cell death.

7 e cell surface upon treatment as a result of immunogenic cell death.

8 s tumour-directed CTL activation by inducing immunogenic cell death.

9 into tissue and elicit inflammation through immunogenic cell death.

10 on with cytotoxic agents on the induction of immunogenic cell death.

11 f DCs during encounter with cells undergoing immunogenic cell death.

12 i-cancer immune response, a process known as immunogenic cell death.

13 modulate the extracellular matrix and induce immunogenic cell death.

14 ic reticulum (ER) stress, which is linked to immunogenic cell death.

15 ll injury profiles with canonical markers of immunogenic cell death.

16 apeutic response via disrupting the onset of immunogenic cell death.

17 amage, all of which cause caspase-1-mediated immunogenic cell death.

18 es exhibited strong cytotoxicity and induced immunogenic cell death.

19 to-CRT are hallmarks of chemotherapy-induced immunogenic cell death(5,6), flavivirus infection and se

20 IRE induces immunogenic cell death, activates dendritic cells, and a

21 Viral infection can trigger immunogenic cell death, activating the immune system aga

22 ing the distinct but interconnected roles of immunogenic cell death, activation of immune cells such

23 ugh the activation of cytosolic immunity and immunogenic cell death and (3) favouring reactogenicity

24 species and killed cancer cells by inducing immunogenic cell death and apoptosis.

25 ociated molecular patterns characteristic of immunogenic cell death and are phagocytosed by macrophag

26 ritical for cancer cell survival, leading to immunogenic cell death and enhanced antitumour immune re

27 PDT promotes immunogenic cell death and enhances immune recognition w

28 ccinia virus VVWR-TK(-)RR(-)-Fcu1 can induce immunogenic cell death and generate a systemic immune re

29 cancer-specific immune responses by inducing immunogenic cell death and other effector mechanisms.

30 s local concentration of doxorubicin induces immunogenic cell death and promotes the recruitment of i

31 eukaryotic transgene payloads, induction of immunogenic cell death and promotion of antitumour immun

32 ecessor Delta-24-RGD, Delta-24-RGDOX induced immunogenic cell death and recruit lymphocytes to the tu

33 r improved anticancer immunity by activating immunogenic cell death and regulating macrophages polari

34 on of GSH to enhance the irradiation-induced immunogenic cell death and subsequent dendritic cell (DC

35 e been suggested as a contributing factor in immunogenic cell death and T cell-mediated immunity.

36 to hyperthermia and doxorubicin resulted in immunogenic cell death and the local release of type I i

37 nhibition of the MAPK and PI3K-AKT pathways, immunogenic cell death and the recruitment of infiltrati

38 Pyroptosis induced immunogenic cell death and the subsequent release of tum

39 lating antigen-presenting cells, PTX induces immunogenic cell death, and CDN activates the STING path

40 ncluding lymphodepletion, T cell priming via immunogenic cell death, and inflammation; all occur with

41 xaliplatin/cyclophosphamide, shown to induce immunogenic cell death, and paclitaxel/carboplatin, repo

42 peutic tools based on their ability to drive immunogenic cell death associated with robust anticancer

43 ical role of sphingolipids in the process of immunogenic cell death associated with the ER stress res

44 diselenide bonds, resulting in DOX-mediated immunogenic cell death at the tumor site.

45 itro, causing cytotoxicity with hallmarks of immunogenic cell death (calreticulin translocation to th

46 n for the exposure of the three hallmarks of immunogenic cell death (calreticulin, HMGB1, and ATP).

47 Both apoptosis and immunogenic cell death contributed to killing of cancer

48 the role of sphingolipids in the process of immunogenic cell death downstream of the protein kinase

49 Pyroptosis is a highly immunogenic cell death due to the release of damage-asso

50 Degradation of RIPK1 by LD4172 triggers immunogenic cell death, enhances tumor-infiltrating lymp

51 rrently, its cytotoxic payload (DXd) induces immunogenic cell death, further activating myeloid cells

52 These ways of dying are termed immunogenic cell death (ICD) and are associated with bio

53 wo polymer-drug conjugates that could induce immunogenic cell death (ICD) and disrupt the PD-L1/PD-1

54 61beta-induced paraptosis, thereby promoting immunogenic cell death (ICD) and systemic anti-tumor res

55 urthermore, SK actually induced satisfactory immunogenic cell death (ICD) and the resulting dendritic

56 Immunogenic cell death (ICD) and tumour-infiltrating T l

57 s issue, chemotherapeutic agents that induce immunogenic cell death (ICD) are being investigated as p

58 Approaches that induce immunogenic cell death (ICD) are expected to eliminate c

59 Major advances stemmed from recognizing immunogenic cell death (ICD) as an RCD type defined by t

60 y in syngeneic mice through the induction of immunogenic cell death (ICD) as well as interfering in t

61 knockdown exhibited the potential to lead to immunogenic cell death (ICD) by impeding the normal clea

62 Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immun

63 Immunogenic cell death (ICD) converts dying cancer cells

64 Moreover, cancer cells succumbing to immunogenic cell death (ICD) expose CALR on their surfac

65 helix secondary structure and induces robust immunogenic cell death (ICD) in cancer cells as characte

66 helix secondary structure and induces robust immunogenic cell death (ICD) in cancer cells as characte

67 NSAID treatment induced hallmarks of immunogenic cell death (ICD) in CRC cells and colonic ep

68 activates Death Receptor 5 (DR5) to trigger immunogenic cell death (ICD) in CRC cells.

69 Suggesting a key role for immunogenic cell death (ICD) in immunosurveillance, both

70 th doxorubicin (DOX), a drug known to induce immunogenic cell death (ICD) in tumor cells, to form DOX

71 The influenza viruses) induce immunogenic cell death (ICD) in tumour cells by triggeri

72 Mechanistically, MFP induced immunogenic cell death (ICD) in vivo and in vitro, as de

73 ed complexes have been recently exploited as immunogenic cell death (ICD) inducers for activating imm

74 liposome formulation to deliver a potential immunogenic cell death (ICD) inducing agent, 17-(allylam

75 Immunogenic cell death (ICD) involves changes in the com

76 Immunogenic cell death (ICD) is a form of regulated cell

77 Immunogenic cell death (ICD) is a special pattern of tum

78 Immunogenic cell death (ICD) is a way of reengaging the

79 Induction of cancer immunogenic cell death (ICD) is one promising way to eli

80 Immunogenic cell death (ICD) is the process by which cer

81 Immunogenic cell death (ICD) occurs when a dying cell re

82 ssociated antigens, can occur in response to immunogenic cell death (ICD) of tumor cells.

83 cial or harmful, which is represented by the immunogenic cell death (ICD) paradigm or overexpression

84 In addition, while immunogenic cell death (ICD) provides a viable approach

85 and exogenous Ca(2+) synergistically trigger immunogenic cell death (ICD) through sustained Ca(2+) ov

86 blate the primary tumor directly and elicits immunogenic cell death (ICD) to promote the immune respo

87 stress-response protein capable of inducing immunogenic cell death (ICD) when translocated to the ce

88 spindle assembly checkpoint (SAC)-dependent immunogenic cell death (ICD), an immune-priming form of

89 fferent types of RCD, including ferroptosis, immunogenic cell death (ICD), and pyroptosis.

90 ts, especially those produced as a result of immunogenic cell death (ICD), are known to be a potentia

91 trolled cell death, especially when inducing immunogenic cell death (ICD), can kill even resistant tu

92 a mode of drug-induced cell death, known as immunogenic cell death (ICD), can propagate antitumoral

93 ainst multiple cancer cell types by inducing immunogenic cell death (ICD), including the release of d

94 A damage repair inhibitor AZD7648 to enhance immunogenic cell death (ICD), the MPD1-based therapy tri

95 dy investigates the synergistic potential of immunogenic cell death (ICD), triggered by chemotherapeu

96 Immunogenic cell death (ICD), which results from insuffi

97 copolymer-epirubicin conjugate that induces immunogenic cell death (ICD), with MPPA, a multivalent H

98 Nano-Folox induced OxP-mediated immunogenic cell death (ICD)-associated antitumor immuni

99 therapeutics, including (but not limited to) immunogenic cell death (ICD)-inducing agents and immune

100 Immunogenic cell death (ICD)-inducing modalities not onl

101 coordinates cell survival, inflammation, and immunogenic cell death (ICD).

102 lar patterns (DAMP), factors known to induce immunogenic cell death (ICD).

103 is), and promoted hallmark danger signals of immunogenic cell death (ICD).

104 osurveillance through the induction of tumor immunogenic cell death (ICD).

105 nduce tumor-specific immune response through immunogenic cell death (ICD).

106 hed peculiar type of tumor cell death called immunogenic cell death (ICD).

107 presentation machinery, and activating tumor immunogenic cell death (ICD).

108 Moreover, treatment with T-Ama induced immunogenic cell death in breast cancer cells and, there

109 Radiation therapy induces immunogenic cell death in cancer cells, whereby released

110 s containing DCF ligands induce hallmarks of immunogenic cell death in cancer cells.

111 lded protein aggregates, ultimately inducing immunogenic cell death in dMMR cancer cells.

112 rest, and tumor immunogenicity and generated immunogenic cell death in human TNBC cell lines.

113 Loss of induction of immunogenic cell death in response to T-DM1 leads to res

114 surgical cavities effectively induces cancer immunogenic cell death in situ and evokes strong T cell-

115 nstrating single-agent efficacy that induces immunogenic cell death in treated tumors.

116 eatment induced an inflammatory response and immunogenic cell death in tumor cells and promoted the i

117 e containing CD40 ligand mRNA induces robust immunogenic cell death in tumoural tissues, leading to t

118 ng of NSCLC cells but also elicited signs of immunogenic cell death including an endoplasmic reticulu

119 pproach to facilitate cancer therapy-induced immunogenic cell death including ATP release and to limi

120 agents triggered apoptosis and hallmarks of immunogenic cell death, including calreticulin exposure,

121 y the small-molecule immunotherapy agent and immunogenic cell death induced by PDT.

122 the lipid-bilayer-crossing capability of the immunogenic cell death inducer doxorubicin, eliminating

123 (5FURW), paired with another common drug and immunogenic cell death inducing agent, doxorubicin (DOX)

124 Accordingly, treatment with immunogenic cell death-inducing chemotherapy sensitized

125 such as p53 mutations, reduced dependence on immunogenic cell death induction, and distinctly attenua

126 m secondary tumor challenge, indicating that immunogenic cell death is induced.

127 uppression in the TME and induction of tumor immunogenic cell death, leading to activation and expans

128 F3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflam

129 0 upregulation in melanoma cells followed by immunogenic cell death, leading to enriched dendritic ce

130 effects of DNA damage did not correlate with immunogenic cell death markers or with the extent of apo

131 Understanding both these pathways of immunogenic cell death may yield novel approaches to reg

132 cell death pathways have emerged, including immunogenic cell death, necroptosis, pyroptosis, and net

133 duction of DR5 by CDK4/6 inhibitors promoted immunogenic cell death of cancer cells.

134 is result suggests that ibrutinib can induce immunogenic cell death of lymphoma cells and that concom

135 OX/GA induces immunogenic cell death of tumor cells and STING activati

136 conventional chemotherapeutics, SCNPs cause immunogenic cell death or ICD.

137 ta indicate that this agent can also promote immunogenic cell death, particularly when used in combin

138 e, the induction of ER stress often leads to immunogenic cell death, providing another factor that co

139 mediated cytotoxicity as a prominent form of immunogenic cell death, resulting in mechanisms that pro

140 ellular survival, inflammatory responses and immunogenic cell death signalling.

141 Immunogenic cell death significantly contributes to the

142 ess, cytoplasmic DNA, and signals related to immunogenic cell death such as calreticulin exposure and

143 RT translocation to the cell surface induces immunogenic cell death, suggesting a role in tumor suppr

144 ancer stem cells with dendritic cells during immunogenic cell death, suggesting this as an important

145 ed molecular patterns (DAMPs), indicating an immunogenic cell death that could potentiate antitumor i

146 ar differences fundamental to tolerogenic or immunogenic cell death, the cells that sense and react t

147 ical evidence indicates that the capacity of immunogenic cell death to (re-)activate an anticancer im

148 tumor therapy via inducing cell apoptosis or immunogenic cell death to prevent recurrence and metasta

149 folded protein response and the induction of immunogenic cell death triggered by the RP11-350G8.5 kno

150 To leverage this immunogenic cell death, we combined MLN4924 treatment wi

151 uration and T cell infiltration mediated via immunogenic cell death were observed in treated mice.

152 perone grp170 in situ strongly promotes the "immunogenic" cell death when delivered to the mda-7/IL-2

153 tumour microenvironment through induction of immunogenic cell death, which also promotes the recruitm

154 been shown that chemoradiotherapy may induce immunogenic cell death, which could trigger T-cell immun

155 ction of safety switch as well as inducer of immunogenic cell death, which in turn stimulates antitum

156 heavily suppresses tumor growth and inducing immunogenic cell death, which is synergistic with Indoxi

157 This ICIE treatment leads to potent immunogenic cell death, which promotes maturation of den